Immunovant (IMVT) Projected to Post Earnings on Friday

Immunovant (NASDAQ:IMVT) will likely be releasing its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.01). During the same quarter in the prior year, the firm earned ($0.74) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Trading Down 2.5%

Shares of IMVT opened at $25.15 on Thursday. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -8.86 and a beta of 0.54. The firm’s fifty day simple moving average is $25.55 and its 200-day simple moving average is $20.66. Immunovant has a twelve month low of $12.72 and a twelve month high of $27.80.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Guggenheim restated a “buy” rating and issued a $41.00 price target on shares of Immunovant in a research note on Thursday, December 18th. The Goldman Sachs Group increased their price objective on Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Truist Financial boosted their target price on Immunovant from $16.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Wolfe Research raised Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Tuesday, January 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunovant currently has an average rating of “Moderate Buy” and an average target price of $30.78.

Insider Activity at Immunovant

In other news, insider Tuyl Christopher Van sold 10,813 shares of Immunovant stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $26.91, for a total value of $290,977.83. Following the transaction, the insider directly owned 149,930 shares of the company’s stock, valued at $4,034,616.30. The trade was a 6.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Andrew J. Fromkin sold 22,249 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $23.25, for a total transaction of $517,289.25. Following the completion of the sale, the director owned 85,852 shares of the company’s stock, valued at approximately $1,996,059. This trade represents a 20.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 63,868 shares of company stock valued at $1,538,470 over the last 90 days. 1.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Prelude Capital Management LLC purchased a new stake in shares of Immunovant in the third quarter valued at approximately $672,000. Algert Global LLC purchased a new position in Immunovant in the third quarter worth $563,000. Creative Planning lifted its holdings in Immunovant by 8.9% in the third quarter. Creative Planning now owns 38,503 shares of the company’s stock valued at $621,000 after acquiring an additional 3,135 shares during the period. LMR Partners LLP acquired a new stake in Immunovant in the second quarter valued at $401,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Immunovant by 4.1% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,641 shares of the company’s stock worth $683,000 after purchasing an additional 1,670 shares in the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.